EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Extracellular ATP-P2RY2 signaling drives intratumoral prostaglandin E2 accumulation and adaptive resistance to immunotherapy in solid tumors

Zhaoqing Hu, Hitoshi Matsuo, Shangce Du, Cecilia Berzain Battioni, Lena Jassowicz, Rafael Carretero, Melanie Sator-Schmitt, Xiyue Zhao, Beiping Miao, Cansu Eris, Helena Engel, Mohamed A A Mahmoud und 5 weitere

Immunity · 2026-07 · 59 (7) · 1928-1947.e8

DOI: 10.1016/j.immuni.2026.06.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunity, 2026-07. Verfasst von Zhaoqing Hu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division Immune Regulation in Cancer, German Cancer Research Center (DKFZ) Heidelberg, 69120 Heidelberg, Germany; Faculty of Biosciences, Heidelberg …. Hauptthemen laut MEDLINE: Dinoprostone, Receptors, Purinergic P2Y2, Adenosine Triphosphate, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Research Foundation, European Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Extracellular ATP (eATP) accumulates in the tumor microenvironment (TME), where its metabolite adenosine is implicated in promoting immunosuppressive pathways. We found that immunotherapy further increased eATP concentrations in the TME. eATP directly signaled through the purinergic receptor P2RY2 in tumor cells to suppress T cell function, independently of its metabolites. Mechanistically, eATP-P2RY2 signaling drove expression of cyclooxygenase (COX)-1 and COX-2 and downstream accumulation of prostaglandin E2 (PGE₂). Genetic deletion or pharmacologic inhibition of P2RY2 reduced baseline intratumoral PGE₂ and prevented therapy-induced PGE₂ accumulation, changed the TME immune infiltrate, restored antitumor T cell responses, and overcame resistance to immune checkpoint blockade, CAR-T, and TCR-T therapies. A P2RY2 antagonist monoclonal antibody recapitulated the in vivo therapeutic benefit and enhanced human autologous tumor-infiltrating lymphocyte responses against matched tumor cells ex vivo. Thus, persistent eATP-P2RY2 signaling in the TME drives a PGE₂-mediated immunosuppressive circuit that operates at baseline and is further amplified during immunotherapy, driving adaptive resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DinoprostoneReceptors, Purinergic P2Y2Adenosine TriphosphateNeoplasmsImmunotherapyAnimalsHumansSignal TransductionTumor MicroenvironmentMiceCell Line, TumorT-LymphocytesDrug Resistance, NeoplasmMice, KnockoutLymphocytes, Tumor-Infiltrating

Stichwörter der Autor:innen

P2RY2PGE(2)T cell therapycancer immunologyextracellular ATPimmune checkpointimmune evasionimmunotherapy resistancepurinergic signalingtumor microenvironment

Substanzen

DinoprostoneReceptors, Purinergic P2Y2Adenosine Triphosphate

Autor:innen und Institutionen

  • Division Immune Regulation in Cancer, German Cancer Research Center (DKFZ) Heidelberg, 69120 Heidelberg, Germany; Faculty of Biosciences, Heidelberg University, 69120 Heidelberg, Germany.
  • Division Immune Regulation in Cancer, German Cancer Research Center (DKFZ) Heidelberg, 69120 Heidelberg, Germany; Faculty of Medicine, Heidelberg University, 69120 Heidelberg, Germany.
  • Division Immune Regulation in Cancer, German Cancer Research Center (DKFZ) Heidelberg, 69120 Heidelberg, Germany.
  • Division of Experimental Neurosurgery, Department of Neurosurgery, Heidelberg University Hospital, Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.
  • DKFZ-Bayer Joint Immunotherapeutics Laboratory, German Cancer Research Center, 69120 Heidelberg , Germany.
  • Department of Immunology, Leiden University Medical Center (LUMC), Leiden 2333 ZA, the Netherlands.

Förderung

  • German Research Foundation
  • European Research Council

Zitieren

APA

Hu, Z., Matsuo, H., Du, S., Berzain Battioni, C., Jassowicz, L., Carretero, R., Sator-Schmitt, M., Zhao, X., Miao, B., Eris, C., Engel, H., Mahmoud, M. A. A., Laport, E., Xiao, Y., Hofmann, I., Herold-Mende, C., & Sun, C. (2026). Extracellular ATP-P2RY2 signaling drives intratumoral prostaglandin E2 accumulation and adaptive resistance to immunotherapy in solid tumors. Immunity, 59(7), 1928-1947.e8. https://doi.org/10.1016/j.immuni.2026.06.006

Vancouver

Hu Z, Matsuo H, Du S, Berzain Battioni C, Jassowicz L, Carretero R, et al. Extracellular ATP-P2RY2 signaling drives intratumoral prostaglandin E2 accumulation and adaptive resistance to immunotherapy in solid tumors. Immunity. 2026;59(7):1928-1947.e8. doi:10.1016/j.immuni.2026.06.006

BibTeX
@article{Hu2026,
  author = {Hu, Zhaoqing and Matsuo, Hitoshi and Du, Shangce and Berzain Battioni, Cecilia and Jassowicz, Lena and Carretero, Rafael and Sator-Schmitt, Melanie and Zhao, Xiyue and Miao, Beiping and Eris, Cansu and Engel, Helena and Mahmoud, Mohamed A A and Laport, Elke and Xiao, Yanling and Hofmann, Ilse and Herold-Mende, Christel and Sun, Chong},
  title = {Extracellular ATP-P2RY2 signaling drives intratumoral prostaglandin E2 accumulation and adaptive resistance to immunotherapy in solid tumors},
  journal = {Immunity},
  year = {2026},
  volume = {59},
  number = {7},
  pages = {1928--1947.e8},
  doi = {10.1016/j.immuni.2026.06.006}
}
Kostenlos starten →